Showing 7411-7420 of 9461 results for "".
- Analysis: Scar Reduction Seen with Fractional CO2 and 5-FU Laser Treatmentshttps://practicaldermatology.com/news/analysis-scar-reduction-seen-fractional-co2-and-5-fu-laser-treatments/2463110/Results from a new meta-analysis suggest that fractional carbon dioxide (FCO2) plus 5-fluorouracil (5-FU) laser therapy was effective in treating hypertrophic and keloid scars. Researchers for the analysis included data from 18 studies (N = 550). The team comprehensively search
- Study: Frequent Dermatologist Visits Boost Melanoma Survival Rateshttps://practicaldermatology.com/news/study-frequent-dermatologist-visits-boost-melanoma-survival-rates/2463097/New research suggests that patients with melanoma who engage in more frequent visits to the dermatologist show higher rates of survival. "Guidelines recommend that patients with melanoma undergo dermatologic examination at least annually," the authors wrote in the Journal of the American
- Dr. Jeanine Downie Discusses Fake Botox in TV Segmenthttps://practicaldermatology.com/news/dr-jeanine-downie-discusses-fake-botox-tv-segment/2463070/If public awareness is the key to combatting the counterfeit Botox problem that has been popping up around the country recently, then Jeanine B. Downie, MD, FAAD, took a big step May 13. Dr. Downie, an Editorial Board member for Practical Dermatology's sister publication Mode
- Consensus Statement Raises Awareness of CTCLhttps://practicaldermatology.com/news/consensus-statement-raises-awareness-ctcl/2463052/Kyowa Kirin, Inc. announced the publication of a patient-focused global consensus statement developed in collaboration with patient advocacy groups, calling on all healthcare authorities, hospitals, and clinicians to undertake 12 specific actions to enhance awareness, diagnosis, care, and support
- Merck Discontinues Testing of Experimental Skin Cancer Combo Therapyhttps://practicaldermatology.com/news/merck-discontinues-testing-experimental-skin-cancer-combo-therapy/2463022/Merck has announced the termination of the vibostolimab and pembrolizumab coformulation arm in the Phase 3 KeyVibe-010 trial, according to a news release from the company. The trial assessed the combination therapy's efficacy compared to KEYTRUDA alone as adjuvant treatment for patients w
- Survey Highlights Increased Risk of Sunburn and Skin Cancer Among Outdoor Workershttps://practicaldermatology.com/news/survey-highlights-increased-risk-sunburn-and-skin-cancer-among-outdoor-workers/2463018/A recent survey conducted by the American Academy of Dermatology (AAD) highlighted the heightened risk of sunburn and skin cancer faced by outdoor workers in the United States. The survey, according to a press release, included responses from more than 1,000 U.S. adults and emphasized the
- Inside LEVEL UP: Lead Investigator Discusses Upadacitinib Studyhttps://practicaldermatology.com/news/inside-level-lead-investigator-discusses-upadacitinib-study/2463017/A recent study produced favorable topline results regarding the efficacy and safety of upadacitinib for adults and adolescents with moderate-to-severe atopic dermatitis (AD) who had an
- Dermal Fillers Connected to Body Dysmorphia Disorder?https://practicaldermatology.com/news/dermal-fillers-connected-body-dysmorphia-disorder/2462981/A recent Forbes article suggests a potential connection between dermal fillers and body dysmorphic disorder (BDD), a condit
- Fish Residues Could Supply Collagenhttps://practicaldermatology.com/news/fish-residues-could-supply-collagen/2462980/Researchers in Norway believe fish residues can supplement current sources of raw materials for collagen and gelatin, according to a Phys.org article. A project called SUPREME, headed by the Norwegian science institute SINTEF Ocean in collaboration with Norwegian university NTNU and the T
- Research Grant Supports Animal-Free Testing for Botoxhttps://practicaldermatology.com/news/research-grant-supports-animal-free-testing-botox/2462979/The National Center for Advancing Translational Services (NCATS) and the US Food and Drug Administration (FDA) awarded a $2 million research grant to develop an advanced testing platform capable of assessing the potency of botulinum toxin without the need for animal testing, according to a press